Pyridoxine-dependent-developmental and epileptic encephalopathy

Pyridoxine-dependent developmental and epileptic encephalopathy (PDE-DEE), also known as pyridoxine-dependent epilepsy (PDE), is a rare inherited metabolic disorder caused by pathogenic variants in the ALDH7A1 gene, which encodes antiquitin (α-aminoadipic semialdehyde dehydrogenase). This enzyme deficiency leads to accumulation of α-aminoadipic semialdehyde (AASA) and piperideine-6-carboxylate (P6C) in body fluids. P6C inactivates pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, which is an essential cofactor for numerous enzymatic reactions in the brain, thereby disrupting neurotransmitter metabolism and causing severe seizures. The condition primarily affects the central nervous system. Seizures typically begin in the neonatal period, often within hours to days after birth, though onset can occasionally occur later in infancy or early childhood. The seizures are characteristically resistant to conventional antiepileptic drugs but respond dramatically to pharmacological doses of pyridoxine (vitamin B6). Without treatment, affected individuals experience recurrent, prolonged seizures and status epilepticus. Even with seizure control through pyridoxine supplementation, many patients experience some degree of developmental delay and intellectual disability, indicating that the underlying metabolic derangement causes neurotoxicity beyond what seizure control alone can address. The mainstay of treatment is lifelong supplementation with pyridoxine (vitamin B6), which controls seizures in most patients. Adjunctive therapy with lysine reduction strategies, including a lysine-restricted diet and supplementation with L-arginine (which competes with lysine for intestinal absorption and cellular transport), has been explored to reduce the accumulation of neurotoxic metabolites and potentially improve neurodevelopmental outcomes. Folinic acid supplementation may also be beneficial, as some cases previously described as folinic acid-responsive seizures were later found to have ALDH7A1 mutations. Early diagnosis through measurement of urinary AASA and genetic testing is critical, as prompt initiation of treatment may improve long-term neurodevelopmental prognosis.

Common questions about Pyridoxine-dependent-developmental and epileptic encephalopathy